Get started
Author

Declan Noone

Observed names: D Noone, D. NOONE, D. Noone, Noone, D., Noone, Declan
Observed institutions: Royal College of Surgeons in Ireland, Trinity College Dublin, Canadian Hemophilia Society, Netherlands Haemophilia Society, BMJ Group (United Kingdom), World Federation of Hemophilia
ORCID: 0000-0003-2183-4277
Observed ORCID: 0000-0003-2183-4277
OpenAlex ID: A5000561395
European principles of care for women and girls with inherited bleeding disorders
2021 · Karin van Galen, Michelle Lavin, et al. · Haemophilia · 83
PDF
Hemophilia treatment in 2021: Choosing the”optimal” treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians
2021 · Cedric Hermans, Declan Noone, et al. · Blood Reviews · 71
PDF
Haemophilia care in Europe – a survey of 35 countries
2013 · B. O'Mahony, D. Noone, et al. · Haemophilia · 71
Treatment for life for severe haemophilia A– A cost‐utility model for prophylaxis vs. on‐demand treatment
2013 · A. Farrugia, J. Cassar, et al. · Haemophilia · 59
Delivery of AAV‐based gene therapy through haemophilia centres—A need for re‐evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC
2021 · Wolfgang Miesbach, Pratima Chowdary, et al. · Haemophilia · 58
PDF
Barriers and challenges faced by women with congenital bleeding disorders in Europe: Results of a patient survey conducted by the European Haemophilia Consortium
2019 · Declan Noone, Naja Skouw‐Rasmussen, et al. · Haemophilia · 57
The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia
2018 · MW. Skinner, C. Chai-Adisaksopha, et al. · Pilot and Feasibility Studies · 55
PDF
A survey of the outcome of prophylaxis, on‐demand treatment or combined treatment in 18–35‐year old men with severe haemophilia in six countries
2012 · D. Noone, B. O'Mahony, et al. · Haemophilia · 54
PDF
Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?
2022 · Maarten J. Postma, Declan Noone, et al. · Orphanet Journal of Rare Diseases · 51
PDF
Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021
2023 · Maria Abbattista, Alessandro Ciavarella, et al. · Journal of Thrombosis and Haemostasis · 41
PDF
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
2022 · Don Husereau, Michael Drummond, et al. · The European Journal of Health Economics · 41
PDF
Non‐severe haemophilia: Is it benign? – Insights from the PROBE study
2020 · Chatree Chai‐Adisaksopha, Declan Noone, et al. · Haemophilia · 37
PDF
A survey of the outcome of prophylaxis, on‐demand or combined treatment in 20–35 year old men with severe haemophilia in four European countries
2011 · D. NOONE, B. O’MAHONY, et al. · Haemophilia · 35
Haemophilia care in Europe: a survey of 19 countries
2010 · B. O’MAHONY, D. NOONE, et al. · Haemophilia · 31
Hemophilia gene therapy: first, do no harm
2023 · Leonard A. Valentino, Radoslaw Kaczmarek, et al. · Journal of Thrombosis and Haemostasis · 29
PDF
Understanding minimum and ideal factor levels for participation in physical activities by people with haemophilia: An expert elicitation exercise
2020 · Antony P. Martin, Tom Burke, et al. · Haemophilia · 26
Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC
2022 · Wolfgang Miesbach, Fariba Baghaei, et al. · Haemophilia · 24
PDF
Survey of coagulation factor concentrates tender and procurement procedures in 38 European Countries
2015 · B. O'Mahony, D. Noone, et al. · Haemophilia · 24
Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?
2020 · Glenn F. Pierce, Radoslaw Kaczmarek, et al. · Haemophilia · 23
PDF
Clinical attributes and treatment characteristics are associated with work productivity and activity impairment in people with severe haemophilia A
2021 · Jamie O’Hara, Declan Noone, et al. · Haemophilia · 21
PDF
Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire
2018 · Chatree Chai-Adisaksopha, Mark W Skinner, et al. · BMJ Open · 21
PDF
Test‐retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains
2018 · Chatree Chai‐Adisaksopha, Mark W. Skinner, et al. · Haemophilia · 19
Accreditation model of European Haemophilia Centres in the era of novel treatments and gene therapy
2023 · Ana Boban, Fariba Baghaei, et al. · Haemophilia · 17
Patient agency: key questions and challenges – A report from the 1st workshop of the EHC Think Tank Workstream on Patient Agency
2022 · Amanda Bok, Declan Noone, et al. · The Journal of Haemophilia Practice · 17
PDF
Evolution of Haemophilia Care in Europe: 10 years of the principles of care
2020 · D. Noone, B. O’Mahony, et al. · Orphanet Journal of Rare Diseases · 15
PDF
Works count: 76
Citation count: 1,197
H-index: 21
I10-index: 35
Year
Topic
Type